迈威生物：两款地舒单抗注射液获得巴基斯坦上市许可

Core Viewpoint - Maiwei Biotech (688062) has received regulatory approval for two biosimilar products in Pakistan, marking a significant milestone for the company and the biosimilar market in the region [1] Group 1: Regulatory Approvals - The Searle Company Limited has notified Maiwei Biotech that its two biosimilar injections, 9MW0311 and 9MW0321, have been approved by the Pakistan Drug Regulatory Authority [1] - This approval represents the first registration of a biosimilar drug for de-sulfanil in Pakistan [1] - The products are marketed under the names Mai Li Shu and Mai Wei Jian in China [1] Group 2: Clinical Trials - Maiwei Biotech has also received an acceptance notice from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection, which is intended for the treatment of pathological scars [1]